Dr. Zelenetz on the Role of Biosimilars in Cancer Care

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Biosimilars will never outperform their ‘original’ counterparts, Zelenetz says. Biosimilars are meant to create competition and cost savings.

The NCCN is tasked with developing treatment guidelines regardless of cost. If guidelines can be followed at a lower cost—with biosimilars—this allows for continued innovation. Zelenetz says his talk was ideal for the audience because community oncologists will eventually be using biosimilars in their practices and they need to learn about them now.

<<<

View more from the 2016 NCCN Annual Conference